Article
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
International journal of hematology - 1 Jun 2021
Nakamura Fumi, Arai Honoka, Nannya Yasuhito, Ichikawa Motoshi, Furuichi Shiho, Nagasawa Fusako, Takahashi Wataru, Handa Tomoyuki, Nakamura Yuko, Tanaka Hiroko, Nakamura Yuka, Sasaki Ko, Miyano Satoru, Ogawa Seishi, Mitani Kinuko
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) are standard therapies for chronic myeloid leukemia (CML) that can eradicate Ph-positive leukemic cells. However, disease control is not achievable in a minority of cases, most commonly due to evolution of TKI-resistant clones. There have also been rare cases of emergence of Ph-negative clones with other cytogenetic abnormalities, and, less commonly, development of Ph-negative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.